GEMoaB Monoclonals GmbH   Report issue

For profit Phase 1
Founded: Dresden Germany (2013)

Organization Overview

First Clinical Trial
2018
NCT03516760
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

GEMoaB Monoclonals GmbH

Active Ingredients

Drugs in Phase 1 Trials (2)

gem333 (1 trial)

gem3psca (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Urogenital Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2